Ascent sold to Watson for $375m
Tuesday, 31 January, 2012
Australia’s fifth largest generic pharmaceutical manufacturer, Ascent Pharmahealth, has been sold by its Bangalore-based parent Strides Arcolab to speciality pharmaceutical company Watson Pharmaceuticals for a sum of $375 million.
Strides offloaded its 94% shareholding, with the remaining 6% being sold off by Ascent CEO and founder Dennis Bastas.
The deal allows Strides to pay down US$250 million of its outstanding debt and to focus on its other core business, Agila.
“The sale of Ascent is a value enhancing and forward-looking initiative for Strides,” said Executive Vice Chairman and Group CEO of Strides, Arun Kumar.
“We have been clear about our intention to focus on our highly attractive steriles segment, which we expect to be our growth engine going forward. The transaction further facilitates the execution of this strategy and unlocks significant value for the Group. Furthermore, the proceeds from the transaction considerably strengthens our balance sheet.”
The deal involved significant due diligence, including a 1000 page report being produced in little over a week.
ADHD drug shows promise for treating meth addiction
A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be...
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
